TECTONIC THERAPEUTIC INC. - COMMON STOCK

Tectonic Announces $185 Million Private Placement

03 Feb 2025 06:30:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

30 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

03 Dec 2024 16:01:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

26 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

11 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

07 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

22 Oct 2024 16:01:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

19 Sep 2024 16:01:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic to Participate in September Investor Conferences

20 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

14 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

30 Jul 2024 16:01:00 By Nasdaq GlobeNewswire